Voltar para Home
  • PORTUGUêS
Our Firm
  • Our essence
  • Social responsibility
  • People management
  • Information Technology and Security
  • Transparency
  • 30 years
  • Contact
What we do
  • Practice areas
  • Our professionals
  • International
  • Attix – Innovation program
Contents
  • Único – News portal
  • Mattos Filho in the media
Join us
  • Careers
  • Open positions
  • Jovens Talentos
  • Soma Talentos
  • Alumni
Idioma
  • PORTUGUêS
Único - The Mattos Filho news portal
Voltar para a página anterior
Disponível em Português
News and Business

New law revokes certain patent-related clauses in Brazil’s Industrial Property Law

Approval from Anvisa no longer necessary for obtaining pharmaceutical patents in Brazil

Disponível em Português
  • News

Assuntos

  • Intellectual property
Publicada em 01/09/2021

​On August 27, 2021, Law No. 14,195 (the ‘Business Environment Law’) was published in the Official Federal Gazette after President Jair Bolsonaro signed the law into effect, although certain clauses were vetoed.

This new law provides for important changes across different sectors of the Brazilian legal system, including the Civil Code, Code of Civil Procedure, Corporations Law, Commercial Representation Law and the Industrial Property Law. It also introduces new rules concerning commercial papers, the facilitation of foreign trade, and the Integrated Asset Recovery System (Sira).

Arising from Provisional Measure No. 1,040/2021 (approved by the House of Representatives in June 2021), the Business Environment Law was approved by the National Congress in early August. Irajá Silvestre Filho, the rapporteur of the Bill in the Senate, suggested some specific amendments during the approval process, however these were then rejected in the House of Representatives.

Amendments to the Industrial Property Law

Article 57, item XXVI of the Business Environment Law revokes Article 229-C and the sole paragraph of Article 40 of the Industrial Property Law (LPI).

Included in the LPI in 2001, Article 229-C determined that patents for pharmaceutical products and processes could not be granted without the Brazilian Health Regulatory Agency’s (Anvisa) prior consent. Anvisa’s jurisdiction and role in the Brazilian patent system had been the subject of debate ever since.

With Article 229-C now revoked, obtaining patents for pharmaceutical products and processes no longer requires Anvisa’s approval, which aims to speed up the patent application process. According to the new legislation, the National Institute of Industrial Property (INPI) will be solely responsible for analyzing and granting applications for these patents.

Article 40, sole paragraph of the LPI had established minimum 10-year and 7-year terms, respectively, for invention and utility model patents, counted from the date they were granted. This provision was already declared unconstitutional on May 6, 2021 in an en banc session before the Supreme Federal Court concerning Direct Action for the Declaration of Unconstitutionality (ADI) No. 5,529, filed in 2016.

The Court’s decision was issued with retroactive effects on patents:

  • Granted based on Article 40, sole paragraph of the LPI;
  • Subject to lawsuits filed on or before April 7, 2021; and
  • Related to pharmaceutical products and health equipment.

However, an exception applies to patents in effect by virtue of Article 40, sole paragraph prior to the judgment of ADI No. 5,529, safeguarding them from any potential effects.

With the Business Environment Law now in effect, all invention and utility model patents will be valid for a period of 20 and 15 years from the date of filing, respectively, as provided for in the head of Article 40 of the LPI.

For further information about this subject, please contact Mattos Filho’s Intellectual Property practice area.

*In collaboration with Lorena Sampaio Pereira.

*The summary of this article is available in French, Japanese and Italian at this link.

Nossos Profissionais

  • Fabio Kujawski

    Fabio Kujawski

  • Paulo Brancher

    Paulo Brancher

  • José Roberto de Almeida Junior

Veja Também

Patent for pharmaceutical cannabidiol-based compound revoked by INPI

Últimas Notícias

Debates na saúde suplementar: sandbox regulatório sobre planos de consultas eletivas e exames e outros temas

Assuntos:

  • Life Sciences e Saúde

Mattos Filho launches third edition of Structural Issues in Law Firm Management

Assuntos:

  • Institutional

New law facilitating competition damage claims takes effect in Brazil

Assuntos:

  • Antitrust
  • Litigation and Arbitration
Our Firm
  • Our essence
  • Social responsibility
  • People management
  • Information Technology and Security
  • Transparency
  • 30 years
  • Contact
What we do
  • Practice areas
  • Our professionals
  • International
  • Attix – Innovation program
Contents
  • Único – News portal
  • Mattos Filho in the media
Join us
  • Careers
  • Open positions
  • Jovens Talentos
  • Soma Talentos
  • Alumni
Onde Estamos
  • São Paulo – Paulista

    Al. Joaquim Eugênio de Lima, 447
    +55 11 3147 7600

  • São Paulo – Faria Lima

    Av. Brg. Faria Lima, 4100 6º andar
    +55 11 3035-4050

  • Rio de Janeiro

    ​​Praia do Flamengo, 200 11º andar
    +55 21 3231 8200

  • Brasília

    SCS Q. 09 Lote C Bloco B, Sala 1205
    Edifício Parque Cidade Corporate
    +55 61 3218 6000

  • New York

    34 East 51st Street, 12th floor
    +1 646 695 1100

  • London

    ​5th floor, 32 Cornhill
    +44 (0)20 7280 0160

  • Instagram
  • LinkedIn
Mattos Filho
Copyright 2026 © Todos os Direitos Reservados. Este site busca seguir parâmetros de acessibilidade e inclusão.
  • Data Privacy Policy
  • Information Security Policy
Logo Mattos Filho

Agradecemos sua visita! Como a Microsoft não oferece mais suporte para o Internet Explorer, recomendamos a utilização de outros navegadores ativos para que você tenha melhor experiência em nosso site.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.